Recruiting

CT & MRI

Sponsor:

Emory University

Code:

NCT07859722

Conditions

Prostate Carcinoma

Stage I Prostate Cancer AJCC v8

Stage II Prostate Cancer AJCC v8

Stage III Prostate Cancer AJCC v8

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Magnetic Resonance Imaging

Questionnaire Administration

Study Details

Brief summary:

This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate cancer. Brachytherapy is a type of radiation therapy in which radioactive implants, such as pellets, seeds, ribbons, wires, needles, balloons, or capsules, are placed in the body, directly into or near the tumor. The radiation is delivered through a flexible tube called a catheter or a larger device called an applicator. Treatment planning, or simulation, is a process used to plan radiation therapy so that the target area is precisely located and marked. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. An MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. The addition of MRI to CT for HDR prostate brachytherapy treatment planning may help patients have less urine leakage and less pain after treatment.

Conditions

Prostate Carcinoma

Stage I Prostate Cancer AJCC v8

Stage II Prostate Cancer AJCC v8

Stage III Prostate Cancer AJCC v8

Study ID

NCT07859722

Start date

Oct 22, 2026

Status verified date

Oct, 2026

Completion date

May 31, 2029

Anticipated

Primary completion date

May 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men ≥ 18 years old
  • Histopathologically confirmed prostate cancer
  • No evidence of regional or distant metastases
  • Plan to undergo curative-intent HDR brachytherapy with or without external beam radiation therapy

Exclusion Criteria:

  • Prior pelvic radiation therapy
  • No prior prostate MRI

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm A (CT, SOC HDR brachytherapy)

Patients undergo treatment planning with a CT scan for HDR brachytherapy.

experimental: Arm B (CT, MRI, SOC HDR brachytherapy)

Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.

Interventions

Magnetic Resonance Imaging

Undergo MRI scan

Questionnaire Administration

Ancillary studies

Primary outcome measure

  • Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score [ Time Frame: At 1 month following treatment ]

Central Contacts and Locations

Central contacts

Locations

Emory Proton Therapy Center

Recruiting

Atlanta, Georgia, United States, 30308

Contacts

Emory University Hospital Midtown

Recruiting

Atlanta, Georgia, United States, 30308

Contacts

Principal Investigator:

Kamran Salari, MD

Emory University Hospital/Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Principal Investigator:

Kamran Salari, MD

More Information

Sponsor

Emory University

Last update posted

Nov 2, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-03. This information was provided to ClinicalTrials.gov by Emory University on 2026-11-02. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.